- Home
- » Tags
- » Eluxadoline
Top View
- Importance of Rectal Urgency in Childhood Irritable Bowel Syndrome
- Evaluation of Chronic Diarrhea Luis S
- Chapter 124 Controlled Substances
- Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
- Comprehensive PREFERRED DRUG LIST
- A Case Study of Eluxadoline and Fatty Meal
- Revised 10/1/2020 GEORGIA MEDICAID FEE-FOR-SERVICE
- 206940Orig1s000
- Delta Opioid Receptor (DOR) Peptidomimetic Ligands
- Drug and Alcohol Abuse Prevention Biennial Review Report Or Contact Ms
- List of Scheduling Actions, Controlled Substances And
- 16 Lc 33 6473S Hb 783 (Sub)
- Recommendations for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
- VIBERZI (Eluxadoline) RATIONALE for INCLUSION in PA PROGRAM
- An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
- IBS-Monograph-2018.Pdf
- Download API Catalog
- Minutes of PRAC Meeting on 01-04 October 2018
- Toward an Effective Peripheral Visceral Analgesic: Responding to the National Opioid Crisis
- VIBERZI (Eluxadoline) Tablets, for Oral Use, CIV 5.3) Initial U.S
- Eluxadoline (Viberzi®) EOCCO POLICY
- PRAC Draft Agenda of Meeting 10-13 February 2020
- Efficacy and Safety of Eluxadoline in Patients with Irritable Bowel
- Australian Public Assessment for Eluxadoline [Viberzi]
- Proposed Regulation of the State Board of Pharmacy
- 206940Orig1s000
- Treatment of Irritable Bowel Syndrome: a Review
- Experimental Therapies in Irritable Bowel Syndrome
- FDA FY 2017 Budget
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- CDR Pharmacoeconomic Reivew Report for Viberzi
- 206940Orig1s000
- Viberzi® (Eluxadoline)
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of Meeting on 10-13 February 2020
- 206940Orig1s000
- Molecular Characterization of Eluxadoline As a Potential Ligand
- Viberzi) Reference Number: CP.PMN.170 Effective Date: 12.01.18 Last Review Date: 11.19 Revision Log Line of Business: Commercial, Medicaid
- S3-LL RDS-Update / Layer, Andresen Et Al, 1
- CDR Clinical Review Report for Viberzi
- HOUSE BILL NO. 1113 of North Dakota
- Minimum Requirements PA PA Criteria 01-20-2021
- Diarrhoea-Predominant IBS Market Firms Up
- Drugs of Abuse (2017 Edition)
- Patient-Centered Management of Irritable Bowel Syndrome
- Kentucky Controlled Substances by Schedule II-V(*Not All Trade Names Included)
- Eluxadoline (VIBERZI)
- Irritable Bowel Syndrome Benson Thomas FRCPC Gastroenterology St